Could cause temporary or reversible harm; serious harm is unlikely.
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.
| Brand name | PRAZOSIN HYDROCHLORIDE |
| Generic name | PRAZOSIN HYDROCHLORIDE |
| Active ingredient(s) | PRAZOSIN HYDROCHLORIDE |
| Distributed by / for | Biocon Pharma Inc., Iselin, NJ |
| NDC | 70377-066-11 |
| Full product label | Prazosin Hydrochloride Capsules, USP, 1mg, 100-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ, Manufactured by: Appco Pharma LLC, Piscataway, NJ, NDC 70377-066-11. |
| Recalling firm | Appco Pharma LLC |
| Distribution | U.S.A. Nationwide |
| Quantity | 88,008 bottles- 100's count |
| Recall initiated | 2026-03-27 |
| Report date | 2026-04-08 |
| Recall completed | — |
| Recall number | D-0419-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Piscataway NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗